951 related articles for article (PubMed ID: 19818996)
21. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
22. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
Lan CY; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
[TBL] [Abstract][Full Text] [Related]
24. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.
Dizon DS; Weitzen S; Rojan A; Schwartz J; Miller J; Disilvestro P; Gordinier ME; Moore R; Tejada-Berges T; Pires L; Legare R; Granai CO
Gynecol Oncol; 2006 Feb; 100(2):417-21. PubMed ID: 16336992
[TBL] [Abstract][Full Text] [Related]
25. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
26. A new prognostic model for FIGO stage 1 epithelial ovarian cancer.
Obermair A; Fuller A; Lopez-Varela E; van Gorp T; Vergote I; Eaton L; Fowler J; Quinn M; Hammond I; Marsden D; Proietto A; Carter J; Davy M; Tripcony L; Abu-Rustum N
Gynecol Oncol; 2007 Mar; 104(3):607-11. PubMed ID: 17092548
[TBL] [Abstract][Full Text] [Related]
27. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
Ma SK; Zhang HT; Wu LY; Liu LY
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
[TBL] [Abstract][Full Text] [Related]
30. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
31. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.
Young RC
Semin Oncol; 2000 Jun; 27(3 Suppl 7):8-10. PubMed ID: 10952120
[TBL] [Abstract][Full Text] [Related]
32. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
33. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M
Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408
[TBL] [Abstract][Full Text] [Related]
34. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
Høgdall CK; Nørgaard-Pedersen B; Mogensen O
Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
[TBL] [Abstract][Full Text] [Related]
37. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
Yen MS; Twu NF; Lai CR; Horng HC; Chao KC; Juang CM
Gynecol Oncol; 2009 Sep; 114(3):415-9. PubMed ID: 19577277
[TBL] [Abstract][Full Text] [Related]
38. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
39. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy.
Mayerhofer K; Bodner K; Bodner-Adler B; Schindl M; Kaider A; Hefler L; Zeillinger R; Leodolter S; Joura EA; Kainz C
Cancer; 2001 Jan; 91(2):388-93. PubMed ID: 11180086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
